A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancie

Type of Cancer
Unknown

Sponsor
Regeneron

Protocol Number
R3767-ONC-1613

To Learn More Call
(201)-510-0950